MyBONIVA® Patient Support Program

Exclusive BONIVA patient relationship program is designed to enhance compliance and persistence.

Patients taking BONIVA will be offered assistance in compliance through this exclusive program
Patients can opt to receive a monthly contact by mail, phone, or e-mail on whatever day of the month they choose; included will be tips for adherence and special savings offers for BONIVA

Options for contacting patients:

Phone

Phone

E-mail
E-mail

U.S. mail
U.S. mail

Patients can enroll by calling 1-888-MyBONIVA or going to www.myBONIVA.com.

Image: MyBONIVA® Patient Support Program

BONIVA is indicated for the management of postmenopausal osteoporosis.

Important Safety Information for BONIVA Tablets
BONIVA Tablets are contraindicated in patients unable to stand or sit upright for at least 60 minutes or with uncorrected hypocalcemia. BONIVA is contraindicated in patients with known hypersensitivity to BONIVA or any of its components. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy. Adequate intake of calcium and vitamin D is important in all patients. BONIVA is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

BONIVA, like other bisphosphonates administered orally, may cause upper gastrointestinal (GI) disorders such as dysphagia, esophagitis and esophageal or gastric ulcer. As aspirin, NSAIDs and bisphosphonates are associated with GI irritation, caution should be exercised when using them concomitantly. BONIVA Tablets should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins). Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures. The overall adverse events profile of BONIVA 2.5 mg daily was similar to that of placebo. In a one-year study comparing BONIVA 150 mg once-monthly and BONIVA 2.5 mg daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events (>5%) regardless of causality were abdominal pain (BONIVA 150 mg 7.8% vs BONIVA 2.5 mg 5.3%), hypertension (6.3% vs 7.3%), dyspepsia (5.6% vs 7.1%), arthralgia (5.6% vs 3.5%), nausea (5.1% vs 4.8%) and diarrhea (5.1% vs 4.1%).

This site is intended for U.S. residents only.

The information provided on this site is for informational purposes only and does not take the place of talking to your healthcare provider about your medical condition or treatment.

Privacy Policy | Legal Statement | Contact Us | Unsubscribe

BONIVA and symbol are trademarks of Roche Therapeutics Inc.
MyBONIVA is a registered trademark of Roche Therapeutics Inc.

GlaxoSmithKline